Princeton rolls out Novartis' Bexsero; Mylan's Coury explains India strategy; Covidien swallowing PillCam maker;

@FiercePharma: ICYMI Friday: The Adcock Ingram sale gets messier, with Bidvest upping stake to block $1.2B CFR Pharma buyout. More | Follow @FiercePharma

@EricPFierce: Former Actavis CEO Robert Wessman gets Iceland to invest $250M in his biosimilars aspirations. Friday's story | Follow @EricPFierce

@CarlyHFierce: Pentagon tasks Pfizer with radically rethinking vaccine development. Story from FierceVaccines | Follow @CarlyHFierce

> The FDA has allowed Princeton University today to start a vaccination program for students using Novartis' ($NVS) meningitis B vaccine Bexsero, which is approved in Europe, Australia and Canada but not yet in the U.S. Release

> The strain of bacterial meningitis that has infected 8 students at Princeton University has also infected four students at the University of California, Santa Barbara, although that college has not yet moved to vaccinate students with Novartis' Bexsero. Story

> Lawyers for former SAC fund manager Mathew Martoma, named in a $276 million insider trading case, claim testimony by SAC Capital Advisors founder Steven Cohen shows their client wasn't involved in the alleged scheme. Story

> Mylan ($MYL) Chairman Robert Coury and President Rajiv Malik say their strategy in India has been to grow organically as well as through acquisitions. Q&A

> Teva Pharmaceutical Industries ($TEVA) says by 2018 its pipeline of new drugs could be producing between $1 billion and $1.5 billion in sales. Story

Medical Device News

@FierceMedDev: Covidien is acquiring Given Imaging, maker of the 'PillCam' oral endoscope, for $860M. More | Follow @FierceMedDev

@MarkHFierce: Zoll won Japanese approval for a next-gen monitor/defibrillator, marking its continued expansion in a giant HC mkt. Release | Follow @MarkHFierce

@MichaelGFierce: IT firm Cerner invests in Dx maker Claritas Genomics. Item | Follow @MichaelGFierce

@GalenMoore: Had breakfast yet? Here's a video of Pillcam's journey through the colon. Video | Follow @GalenMoore

> FDA asserts support for consumer genetic tests despite 23andMe crackdown. More

> Robert Langer co-founds a French wound-closure startup with a $10.8M Series A. Story

> Boston Scientific's departing CFO leads massive exec stock sell-off. Article

Biotech News

@FierceBiotech: 2013 American Society of Hematology annual meeting roundup: AbbVie, Gilead join Novartis in the center ring. Coverage | Follow @FierceBiotech

@JohnCFierce: Biogen forges a $200M preclinical Alzheimer's drug deal with Proteostasis. Story | Follow @JohnCFierce

@DamianFierce: "People who should have died 5 yrs ago are alive and well and in complete remission. It's a huge... shift." Story from Bloomberg | Follow @DamianFierce

@EmilyMFierce: A dried-up antibiotics pipeline has led two scientists to launch a crowdsourcing campaign for antibiotics research. Story | Follow @EmilyMFierce

> Novartis/Penn's customized T cell wows ASH with stellar leukemia data. More

> New era for hep C treatment begins with FDA OK for Gilead's sofosbuvir. Article

> Novartis is budgeting $6B a year for bolt-ons. Item

CRO News

> Sarah Cannon buys a clinical trial outfit to expand its cancer reach. Story

> Fast-growing Agilux doubles its preclinical space. News

> Venn snags an Irish CRO in its global buyout push. Report

> Charles River recruits Sloan-Kettering CEO to bolster its science. More

> Pfizer's unlocked trial data could be a boon to CROs. Article

> Sluggish Parexel could be poised for a long-term turnaround. Item

Biotech IT News

> Pfizer is opening up clinical trial data to researchers, patients starting in 2014. Report

> Wanted: 1,000 citizen scientists to crowdsource antibiotics research. Story

> Report tips analytics to get biopharma out of its productivity slump. News

> U.K. sets up $16M competition to find genome data analysis tools. Article

> Text mining 88,000 papers gives Pfizer a drug safety database. More

> Machine learning improves accuracy of flu forecasts. Item

And Finally... Covidien ($COV) will pay $860 million to buy Israel-based Given Imaging ($GIVN), which makes PillCam, the encapsulated endoscope that patients swallow. Story

Suggested Articles

After Trump's "Buy American" executive order for essential medicines, the pharma industry is pushing back.

The U.S. is slamming the brakes on its $765 million loan to Kodak amid insider trading allegations and questions about its fitness for the job.

When it comes to COVID-19 vaccines and treatments, more news is good news. That’s the latest takeaway from consumer sentiment tracking by Harris Poll.